-
Altimmune Inc. NASDAQ:ALT Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).
Location: 910 Clopper Rd Ste 201S, Maryland, 20878-1361, US | Website: www.altimmune.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
279.7M
Cash
164.9M
Avg Qtr Burn
-17.87M
Short % of Float
31.01%
Insider Ownership
0.80%
Institutional Own.
60.59%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details metabolic dysfunction-associated steatohepatitis | Phase 2b Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Phase 2 Update | ||
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Type 2 diabetes | Phase 1b Update | |
AdCOVID Details COVID-19 | Failed Discontinued | |
NasoShield (Vaccine) Details Anthrax, Bacterial infection | Failed Discontinued | |
HepTCell Details Chronic hepatitis B | Failed Discontinued | |
T-COVID Details COVID-19 | Failed Discontinued | |
NasoVAX Details Influenza | Failed Discontinued |